Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Oncocross Co. Ltd. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners, which indicates that each individual case is receiving a unique evaluation. This lack of examiner overlap suggests that the company must tailor its arguments to 3 different sets of examiner preferences and communication styles to move its applications forward.
The 3 pending office actions are situated within 2 distinct art units. This concentration in a small number of art units relative to the number of examiners implies that while the personnel differ, the technical subject matter remains focused. DEKARSKE, MADELINE MCGUIRE is the busiest examiner for this portfolio, currently overseeing 1 pending office action, which confirms that the workload is evenly spread across the 3 distinct examiners.
For a practitioner, the presence of 3 distinct examiners across 2 distinct art units suggests a need for diverse advocacy within a narrow technical field. The fact that the busiest examiner, DEKARSKE, MADELINE MCGUIRE, holds only 1 pending office action means that no single official dominates the current prosecution landscape. This portfolio structure requires monitoring the specific tendencies of each examiner to ensure consistent results across the 2 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| HAYES, JONATHAN EDWARD | 1 | 36.4% | +20.7% |
| RUIZ, JOSHUA DAMIAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285820 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | DEKARSKE, MADELINE MCGUIRE | 23d overdue |
| 17918977 | METHOD FOR ESTIMATING TISSUE-LEVEL INFORMATION FROM CELLULAR-LEVEL INFORMATION, AND DEVICE THEREFOR | RUIZ, JOSHUA DAMIAN | 14d |
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 3684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18285820 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112Other | Non-Final OA | 23d overdue | Pending | Oct 05, 2023 |
| 18278887 | METHOD FOR DIAGNOSING CANCER OF UNKNOWN PRIMARY SITE BY USING ARTIFICIAL INTELLIGENCE | HAYES, JONATHAN EDWARD | — | §101§103§112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 17918977 | METHOD FOR ESTIMATING TISSUE-LEVEL INFORMATION FROM CELLULAR-LEVEL INFORMATION, AND DEVICE THEREFOR | RUIZ, JOSHUA DAMIAN | 3684 | §103 | Final Rejection | 14d | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial